Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Andrew Spencer

Andrew Spencer

Alfred Health-Monash University, Melbourne, Australia

Andrew Spencer, MD, PhD, is head of the Malignant Hematology and Stem Cell Transplantation Service at the Alfred Hospital since 2007, where he established a first-in-human and early phase hematology clinical research unit. Along with this role, he is Professor of Hematology at Monash University, Head of the Myeloma Research Group and Co-Director of the Australian Cancer Research Foundation Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases.

Prof. Spencer’s research program has been focused on identifying novel therapy strategies for multiple myeloma (MM) through the identification of drug resistance processes and biomarkers of drug responsiveness. Additionally, Prof. Spencer is enthusiastic about optimizing the utility of MRD in clinical practice; thus, he explores the role of different modalities of MRD detection in MM. He has over 185 publications, has been invited to speak at numerous international meetings, and is an invited investigator of the International Myeloma Foundation’s Black Swan Research Initiative.

Along with his current roles, Prof. Spencer serves on the steering committee for the global MM registry initiative INSIGHT.